Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 124.57
Day High 126.75
Open:126.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
PR Newswire - Mon Sep 17, 5:00AM CDT
PR Newswire - CMTX
Mon Sep 17, 5:00AM CDT
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million up-front, plus up to $340 million in developmental milestones and up to low double-digit royalties.
IN(3D)USTRY to Gather the Latest 3D-printing Medical Applications
- CNW Group - Thu Sep 13, 6:18AM CDT
CNW Group - CMTX
Thu Sep 13, 6:18AM CDT
The third edition of In(3D)ustry (http://www.in3dustry.com) will showcase some of the main 3D-printing applications in the medical sector, one of the most innovative sectors that uses this technology. Among the speakers participating are representatives from GE Venture Healthcare, United Therapeutics, Aprecia Pharmaceutical and 3DHEALS, among others.
CORRECTION - Fira de Barcelona: IN(3D)USTRY to Gather the Latest 3D-printing Medical Applications
PR Newswire - Thu Sep 13, 5:59AM CDT
PR Newswire - CMTX
Thu Sep 13, 5:59AM CDT
In the news release, "IN(3D)USTRY to Gather the Latest 3D-printing Medical Applications" issued on 13 Sep 2018 10:59 GMT, by Fira de Barcelona over PR Newswire, we are advised by a representative of the company that the 3rd paragraph should have read 'In this sense, the show will feature leading international speakers as Dr. Jaedeok Yoo, researcher and founder of Aprecia Pharmaceuticals and specialized in the manufacture of 3D drugs that allows the customization of drug dosage according to the specific needs of every patient and also the acceleration of its dissolution improving its morphology.' Complete, corrected release follows:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 116.69 +7.56% increase
on 09/07/18
Period Open:123.92
Price movement based on the high, low and last over the given period.
127.79 -1.78% decrease
on 09/19/18
+1.59 (+1.28%) increase
since 08/24/18
3-Month 107.08 +17.21% increase
on 06/28/18
Period Open:113.50
Price movement based on the high, low and last over the given period.
130.00 -3.45% decrease
on 08/17/18
+12.01 (+10.58%) increase
since 06/25/18
52-Week 100.57 +24.80% increase
on 05/11/18
Period Open:119.64
Price movement based on the high, low and last over the given period.
152.55 -17.73% decrease
on 01/03/18
+5.87 (+4.91%) increase
since 09/25/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement